WCG Clinical Announces Relaunch of FDAnews as the Premier Source for Drug and Device Insights
WCG Clinical Announces Relaunch of FDAnews as the Premier Source for Drug and Device Insights
PRINCETON, N.J., April 3, 2023 /PRNewswire/ -- WCG Clinical announces the relaunch of its publication FDAnews, a trusted resource for pharmaceutical and medical device insights for more than 50 years. The relaunch will combine the products Drug Industry Daily, Device Daily Bulletin Premium, Drug Daily Bulletin and Device Daily Bulletin into one content destination at FDAnews.com.
新澤西州普林斯頓，2023 年 4 月 3 日 /PRNewswire/ — WCG Clinical 宣佈重新發布其出版物 FDANews， 50 多年來值得信賴的製藥和醫療設備洞察資源。重新發布將合併這些產品 《製藥行業日報》、《設備日報》高級版， 《毒品日報》 和 設備每日公告 進入一個內容目的地 FDanews.com。
In addition to free, breaking news headlines that are available to all readers, FDAnews' premium customers will have access to daily content on:
除了向所有讀者提供的免費突發新聞頭條外， FDaNews' 高級客戶將可以訪問以下內容的每日內容：
- Draft and final guidance from the FDA and other regulatory agencies
- Company mergers and technology developments
- FDA budgets and spending, including proposals and approvals by Congress and the President
- FDA inspection policies, practices, and enforcement activities
- Global enforcement and supply chain trends
- Pharmacovigilance developments
- 來自FDA和其他監管機構的指南草案和最終指南
- 公司合併和技術發展
- 美國食品和藥物管理局的預算和支出，包括國會和總統的提案和批准
- FDA 的檢查政策、做法和執法活動
- 全球執法和供應鏈趨勢
- 藥物警戒的發展
Additional premium features provided by FDAnews' team of industry journalists and subject matter experts from its newly formed editorial board will include:
提供的其他高級功能 FDaNews' 來自其新成立的編輯委員會的行業記者和主題專家團隊將包括：
- In-depth exposés into essential pharmaceutical and device issues
- Reports and perspective on Form 483s, warning letters, recalls, and FDA policy notices and other reports
- Thought pieces, columns, and exclusive perspective on trending topics
- Excerpts of best-selling FDAnews webinar and book content
- 深入了解基本的藥品和器械問題
- 483 表格、警告信、召回、FDA 政策通知和其他報告的報告和觀點
- 關於熱門話題的思想文章、專欄和獨家觀點
- 暢銷書摘錄 FDANews 網絡研討會和書籍內容
The impetus for these changes is in response to feedback from the publications' readers. "Each business day, the new FDAnews will deliver precisely what pharmaceutical and medical device manufacturers have told us they need to know about regulatory compliance and good manufacturing practices," said Terri Moench, RPh, MS, President, Research Solutions for WCG. "Beyond the news, it is our goal is to offer the interpretation of industry changes that manufacturing professionals need to stay in compliance and thrive."
這些變化的推動力是對出版物讀者的反饋的回應。 “每個工作日，新的 FDANews 將提供製藥和醫療器械製造商告訴我們他們需要了解的監管合規性和良好生產規範。” WCG研究解決方案總裁RpH、MS Terri Moench說。“除了新聞之外，我們的目標是爲製造業專業人員保持合規和蓬勃發展所需的行業變化提供解讀。”
Readers who are not yet subscribed for premium content can visit the website daily for free headlines or sign up for a collection of the week's free stories with the newsletters FDAnews, Drug Weekly, or FDAnews Device Weekly.
尚未訂閱優質內容的讀者可以每天訪問該網站以獲取免費頭條新聞，也可以通過時事通訊註冊本週的免費故事集 FDANews，《毒品週刊》， 要麼 FDANews 設備週刊。
Individual subscriptions, customized multi-user, and company licenses to FDAnews are also available. Contact Will Tuttle, Business Development Representative at [email protected] or +1 612.216.2948 to receive a custom quote.
個人訂閱、自定義多用戶和公司許可證 FDANews 也可用。致電 [email protected] 或 +1 612.216.2948 聯繫業務發展代表威爾·塔特爾獲取定製報價。
About WCG FDAnews:
WCG FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on WCG FDAnews' newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations. Learn more at fdanews.com.
關於 WCG FDANews:
WCG FDANews 是爲受美國食品藥品管理局和歐洲藥品管理局監管行業的高管提供國內和國際監管、立法和商業新聞和信息的主要提供商。製藥和醫療器械專業人士信賴 WCG FDANews'時事通訊、書籍、數據庫、網絡研討會和會議，以遵守國際標準和FDA複雜而不斷變化的法規。要了解更多信息，請訪問 fdanews.com。
About WCG:
WCG is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry's first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. For more information, please visit , or follow us on Twitter @WCGClinical or LinkedIn.
關於 WCG：
WCG是全球領先的解決方案提供商，這些解決方案可以顯著提高臨床研究的質量和效率。WCG由兩個部門組成，即業界第一個中央IRB（WCG IRB）和第一個臨床服務組織，使生物製藥公司、CRO和機構能夠推進向患者提供新療法和療法，同時保持人類參與者保護的最高標準。欲了解更多信息，請訪問或在 Twitter @WCGClinical 或 LinkedIn 上關注我們。
SOURCE WCG
來源 WCG
譯文內容由第三人軟體翻譯。